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Abstract
There is irrefutable evidence for the effectiveness of botulinum toxin (BoNT) in the
treatment  of  various  disorders  associated  with  excessive  muscle  contraction  or
autonomic dysfunction. One of the earliest indications as well as the most common
BoNT treated movement disorder is dystonia, predominantly its focal forms, including
blepharospasm,  oromandibular,  spasmodic,  cervical  and  limb  dystonia.  Spastic
disorders comprise another area where BoNT treatment has proved beneficial. Optimal
therapeutic results, however, depend on several factors, including the BoNT serotype,
dose,  concentration,  injected  volume,  frequency  of  application,  as  well  as  precise
localization  of  the  muscles  producing  the  abnormal  movement.  The  accuracy  in
targeting muscle  localization is  considered to  be  a  key factor  for  determining the
outcome of BoNT injections, even more important than dilution volume and dose.
Various techniques to find the best injection site for the delivery of BoNT have been
described in the literature. An attempt was made to summarize in one place the available
evidence, and when possible to compare and point out the advantages and disadvan‐
tages of different techniques for localization of BoNT injections. The widely applied
clinical indications for dystonia and spasticity have been specifically chosen as our focus
in this present work.
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1. Introduction
Botulinum toxin (BoNT), the most potent biological toxin, has become a powerful therapeutic
tool for a growing number of clinical indications. There are seven distinct serotypes of BoNT
—A, B, C (C‐1, C‐2), D, E, F, and G—that have similar neurotoxic properties resulting in flaccid
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muscle  paralysis  due  to  presynaptic  blockage  of  acetylcholine  release  [1].  Double‐blind
placebo‐controlled studies, as well as open‐label clinical trials, provide evidence that when
appropriate  targets  and  doses  are  selected,  BoNT  temporarily  ameliorates  disorders
associated with excessive muscle contraction or autonomic dysfunction [2]. BoNT/A and B are
the most studied serotypes, commercially available and extensively used. Today BoNT/A is
employed and considered safe  and effective  for  treatment  of  movement  disorders,  with
dystonia and spasticity being the most widely used indications. The BoNT serotypes, however,
differ in their intracellular protein target, potency, and duration of action. These properties
differ even between preparations that contain the same BoNT serotype due to variations in
product formulations [3]. Recent changes to the established drug names were intended to
reinforce these differences and prevent medication errors. The products and their approved
indications include the following: onabotulinumtoxin A (Botox, Botox Cosmetic)—cervical
dystonia (CD), severe primary axillary hyperhidrosis, strabismus, blepharospasm, upper and
lower limb spasticity, overactive bladder, urinary incontinence, and migraine headache (Food
and Drug Administration (FDA)). In the European Union (EU), it was approved also for the
treatment of hemifacial spasm. Abobotulinumtoxin A (Dysport)—cervical dystonia, upper
limb spasticity,  moderate‐to‐severe glabellar lines (FDA),  plus blepharospasm, hemifacial
spasm, hyperhidrosis, strabismus, and cerebral palsy (EU). Incobotulinumtoxin A (Xeomin)
—cervical dystonia, blepharospasm, upper limb spasticity, and glabellar lines. Rimabotuli‐
numtoxin B (Myobloc, NeuroBloc)—cervical dystonia [4].
A retrospective long‐term (10 year) BoNT/B study showed that although most patients
required increased dosage, BoNT/B was an effective and safe treatment for a variety of
movement disorders [5]. BoNT/F has been intensively tested, but due to its short‐term effect,
lasting about a month, it is not widely used in clinical practice [6].
The effectiveness of BoNT treatment depends on the proper selection of indications, protein
content of the formulation, frequency of applications, dose, concentration, and injecting
volume. It is also critically dependent on the appropriate localization of the intended target
muscle(s), producing the abnormal movement, be it dystonic or spastic [7]. However, it is
necessary not only to identify the proper muscles but also to localize the injection tip in a
specific muscle area, namely the motor end‐plate zone. A recent study compared low‐dose
BoNT injections applied into the end‐plate zone with those injected at fixed distances from it
at the same muscle. Injections only 1 cm apart reduced the effect of BoNT by 46%. Thus, precise
end‐plate‐targeted injections increase the effect of BoNT and may reduce the required dosage,
treatment costs, and also minimize side effects such as unwanted weakness of adjacent
muscles [8]. However, motor end‐plate zone location is not always easy to find. In order to
facilitate its targeting, some efforts have been made for establishing the localization of the end‐
plate zone in different muscles in reference to external anatomical landmarks [9–11]. Another
phenomenon that should be kept in mind is the diffusion of the toxin, after injection, because
it may be a reason for the weakness of adjacent uninjected muscles. Diffusion may be
influenced by the BoNT serotype and occur in direct proportion to the concentration of BoNT.
Small size of target muscle and increased distance of needle tip from the neuromuscular
junction can also result in increased diffusion of BoNT locally. This diffusion may be advan‐
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tageous, however, when injecting muscles in children who may not be able to tolerate the pain
associated with attempts to target the muscle. On the other hand, when treating dystonia or
spasticity, diffusion of BoNT is clearly undesirable [12]. As BoNT diffusion correlates with
dose, it once again favours injecting into the motor end-plate zone where administering a lower
dose of the toxin provides satisfactory disease control with the possibility for less side effects.
Not only higher doses but also the administration of injections in intervals shorter than 3
months is associated with the development of BoNT antibodies, leading to resistance to the
specific BoNT serotype used [13]. Thus, there is a general consensus among experts that
selection of the appropriate muscle and subsequent injection of the optimal dose are the most
important determinants of the outcome of BoNT treatment [14].
A literature review was performed in order to summarize, and when possible, to compare and
point out the advantages and disadvantages of different techniques for localization of BoNT
injection. Revised techniques comprised clinically established specific sites of injecting
commonly affected muscles in focal dystonia and spasticity, as well as several techniques
facilitating the injection accuracy including electromyography (EMG): passive EMG (EMG
guidance; EMG monitoring) and active EMG guidance (electrical stimulation), imaging, or
endoscopic guidance.
2. Dystonia
Dystonia is a movement disorder characterized by sustained or intermittent muscle contrac-
tions that cause twisting and repetitive movements, abnormal postures, or both. It results from
involuntary concomitant contraction of agonist and antagonist muscles, with overflow of
unwanted muscle contractions into adjacent muscles. Dystonia may be clinically classified
according to its distribution as focal dystonia (affecting a single body part in isolation),
segmental dystonia, hemidystonia, and generalized dystonia [15]. Primary dystonia is the most
common type and primary focal dystonia is 10 times as common as primary generalized
torsion dystonia. Primary focal dystonia occurs nearly always in adults and may involve the
neck, face, or arm, whereas the leg is rarely involved [16].
Localized BoNT injections provide a symptomatic relief in primary and non-primary dystonia
syndromes, as demonstrated by several randomized controlled trials and by a large number
of uncontrolled studies. BoNT is the first-choice treatment for most types of focal dystonia and
could be an effective treatment option for some segmental forms. The effect begins usually
about a week after injections and lasts for about 3 months [4, 17].
2.1. Blepharospasm
Blepharospasm is the second most common form of focal dystonia. Blepharospasm describes
dystonia in the orbicularis oculi and, optionally, its adjacent muscles, including the corrugator
supercilii, procerus, nasalis, and levator labii superioris alaeque nasi muscles [7]. It usually
affects both eyes and is characterized by noticeably increased frequency of blink rate, enduring
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spasms of eyelids. It could significantly impair the voluntary eyelid opening which, in extreme
cases, may render the patient functionally blind [18].
BoNT therapy is the treatment of choice for blepharospasm with a 90% efficacy rate of BoNT/
A injections and is also safe during long‐term treatment [19–23]. Evidence supported a Level
A recommendation for BoNT/A, A/Inco, and A/Ona; a Level B recommendation for A/Abo;
and a Level U recommendation for B/Rima [17, 24]. Adverse events include ptosis, tearing,
blurred vision, double vision, dry eyes, and facial weakness [25]. Distant side effects are dose
dependent and likely a result of toxin entering the circulatory or lymphatic system. Therefore,
delivering the least effective amount of toxin in the most accurate manner decreases the risk
of unwanted local and distant side effects as well as the risk of the development of neutralizing
antibodies [23, 26, 27].
2.1.1. Anatomic/clinical muscle selection and localization of the injection needle
Although the beneficial effects of BoNT/A are self‐evident, there are still several unresolved
problems, referred to the optimal injection sites of BoNT [28].
The orbicularis oculi muscle consists of three portions: orbital portion, surrounding the orbital
margin, including the brow, palpebral, and pretarsal portion [7]. The orbicularis oculi muscles
lie immediately beneath the skin, and it is recommended that there is no need of EMG control
during BoNT application [26, 29–31]. The muscle is readily accessible with a 27‐, 30‐, or 32‐
gauge needle [26, 30, 32]. Subcutaneous injections will readily spread into the underlying
orbicularis muscle. A highly recommended injection strategy is the application of two
injections into the upper lid near the canthus medially and laterally in order to avoid the bulk
of the levator palpebrae muscle and consequent ptosis. Two lower lid injections are applied to
the middle portion and to the lower lateral canthus, respectively. Avoiding the medial canthus
spares the nasolacrimal apparatus [33]. A prospective trial compared four different patterns
of injection sites: standard (medial and lateral aspects of the upper eyelid, and lateral and
central portion of the lower eyelid), brow, inner orbital, and outer orbital. The inner orbital
treatment produced significantly more episodes of ptosis (13%) and the standard the highest
rate of epiphora and ocular irritation (18%). Thus, the further away from the eyelid margin the
injection was, the lower risk of ocular side effects occurred [34]. Other studies summarized
that the orbital portion of the orbicularis muscle should be injected at three to six sites
peripherally to the orbital rim [30] and the periocular region might be injected at five to eight
sites, depending on the severity and duration of the problem [35]. Mimic muscles adjacent to
the orbicularis oculi, such as the procerus, the corrugator supercilii, and the nasalis muscles,
may also be used as target muscles [7, 26].
Data of more special interest suggested that BoNT injections into the pretarsal portion of
orbicularis oculi muscles increased the magnitude of the therapeutic response and decreased
the number of unsuccessful treatments and ptosis [18, 32]. Aramideh et al. (1995) compared
the response to BoNT/A according to a triple injection technique (two injections into the upper
eyelid and one injection into the lower eyelid) and injections additionally applied into the
pretarsal portion. The number of successful treatments with the additional pretarsal injections
increased significantly from 81% to 95%, and ptosis occurred significantly less often [28].
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Another study also confirmed the superior efficacy of pretarsal rather than orbital injections
in 49 primary and secondary non‐responders with blepharospasm [36]. A controlled study of
32 [37] and another study of 25 patients with blepharospasm [38] also revealed that pretarsal
injections rather than preseptal injections were associated with better efficacy and significantly
less ptosis. In 10 blepharospasm patients treated unsuccessfully with conventional bilateral
periorbital injections, injecting BoNT into the pretarsal region proved to be highly effective,
while the amount of toxin used was considerably less than that used in conventional methods
[39].
2.1.2. Electromyography-controlled BoNT applications
Although EMG examination is not a routine strategy for localization of the injections [31, 32],
a number of studies used EMG as a guide for accuracy in injecting BoNT into different portions
of orbicularis oculi and in some other facial muscles [23, 28].
Besides, EMG studies of the levator palpebrae and orbicularis oculi muscles are instrumental
in improving the understanding of the variable responses to BoNT application [26, 40, 41].
2.2. Oromandibular dystonia
Phenomenologically, there are seven types of oromandibular dystonia (OMD): jaw‐closing
dystonia (JCD), jaw‐opening dystonia (JOD), jaw‐deviation dystonia (JDD), lip and perioral
dystonia, lingual dystonia, pharyngeal dystonia, and combinations. Most of the patients suffer
from JCD [42]. Associated features may include protrusion or twisting of the tongue, as well
as the involvement of facial, neck, and pharyngeal muscles [7].
OMD responds poorly to systemic therapy, yet a number of small open‐label trials indicated
significant improvement with BoNT/A injection [18]. Patients with JCD have a better response
on BoNT therapy than patients with the other types of movements (JOD or JDD) [43]. JCD
injections include the masseters and the temporal muscles; medial pterygoids may also be
targeted. In JOD, the focus should be primarily on the lateral pterygoids. The submentalis
complex (mylohyoid, geniohyoid, and anterior digastric muscles) has been targeted as well
[33].
Palpation may be a helpful approach, but not all muscles are palpable. Another strategy may
be to monitor muscle activity by EMG (passive EMG guidance) and inject those that showed
increased activity during the particular abnormal movement or posture. However, this is not
always possible because EMG recordings of all involved muscles during action dystonia, such
as OMD, are technically difficult [42].
2.2.1. Anatomic/clinical muscle selection and localization of the injection needle
In a prospective study of 162 patients, the muscle selection was based on clinical observation
and examination coupled with extensive, long‐term experience. The masseters and submental
muscles were injected with BoNT/A. With a moderate‐to‐marked improvement, responded
80% of the JCD; 40% of JOD, 33% of JDD, and 52% of the combinations. Complications such
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as dysphagia and dysarthria were reported in 19% of the JCD and in 40% of the JOD patients.
There was a poorer response and higher complication rate in the JOD than in the JCD [43].
Later on, the study group has modified its technique by directing the injection needle into the
most anterior portion of the submental complex and administering the total dosage as a single
bolus, which resulted in a marked reduction in dysphagia and other complications [42].
2.2.2. Electromyography-controlled BoNT applications
Brin et al. (1994) described their experience with 96 patients with OMD. Muscle selection was
made using EMG and a relatively large number of muscles were considered for injection. EMG
was always used to inject the pterygoids (preferentially the external pterygoids) and usually
to inject the other muscles. If necessary, the digastrics and submentals were also injected. In
all movement categories, patients’ function improved from about 30% of normal function to
about 74%. Adverse effects were seen in 14% of the patients. Only one case of dysphagia was
severe enough to require a change in diet. Most cases of dysphagia were seen in the patients
with JOD and were associated with injection of the digastrics [42, 44]. Because of different
methods of muscle selection and different injection techniques (clinical and EMG) used by Tan
et al. (1999) and Brin et al. (1994), as well as different methods of assessing severity, response,
and adverse effects, it is impossible to compare the two studies; the overall results, however,
appeared to be similar [42].
An open‐label BoNT/A treatment trial of X‐linked dystonia‐parkinsonism reported 50 cases of
OMD and 35 cases of lingual dystonia to be injected under EMG guidance. The OMD group
included 32 cases with JOD, 12 cases with JCD, and 6 cases with JDD. The lingual dystonia
group consisted of 27 cases with tongue protrusion and 8 cases with tongue curling. All the
OMD types as well as lingual dystonias showed substantial improvement at week 4. Adverse
events occurred in 19% of the JOD and in 17% of the JCD patients, as the most frequent of them
were mouth dryness and dysphagia. The investigators observed higher rate of mouth dryness,
particularly with percutaneous lateral pterygoid injections. On the other hand, they stated an
opinion that the lateral pterygoid should be injected, as it was a major force producer in JOD,
and the treated dystonia was severe, with associated pain. The bilateral intraoral approach
under EMG guidance appeared to be safer, faster, and more convenient, rather than the
percutaneous approach when treating JOD. The most common adverse event during the
lingual dystonia treatment was dysphagia, which occurred in 19% of the tongue protrusion
and in 13% of the tongue curling cases [45].
A study evaluated 45 patients treated with quantitative EMG‐guided injections of BoNT for
OMD: 11 patients with JCD, 7 with JOD, and 13 patients with OMD of mixed type. Marked
effect was observed in 70% of the cases. Side effects occurred in 35.6%, most frequently as
transient mild dysphagia, thus indicating quantitative EMG BoNT treatment was safe and
effective [46]. A report of four cases with OMD that involved the lateral pterygoid muscles
producing incapacitating protrusive and lateral jaw movements and displacements used
graphic assessment of jaw movements by a magnetic tracking system. The EMG activity was
recorded by needle electrodes applying an intraoral approach, whereas the activity of masseter
muscles was recorded with surface electrodes. EMG‐guided BoNT injections into the muscles
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led to marked reduction of the OMD severity, the mandibular movements, and the functional
disturbances [47].
In general, the use of EMG has been suggested for muscles that are not superficially palpable,
but it has not been validated [18]. Recently, some authors recommend all injections for OMD
to be complemented with EMG guidance and performed with a hollow, 27‐gauge, Teflon‐
coated, monopolar needle. To minimize the risk of contamination, the intraoral injections
should be administered last [30, 48]. Other authors indicated that pterygoid muscle injections
have to be performed with EMG guidance, as the muscles are not easily accessible to palpation.
The EMG‐guided approach was often helpful for other jaw muscles, such as the digastric,
masseter, and temporalis [4].
In some forms of lingual dystonia, as with the case of tongue protrusion dystonia, because of
the various muscles involved in tongue protrusion, as well as jaw opening, they could not be
reliably differentiated either clinically or by EMG sampling. This, however, did not hamper
the good results from BoNT injections in the ‘submental muscles’, although some swallowing
difficulties could be triggered [42]. There are still unresolved issues concerning the best method
of identifying and selectively injecting the most appropriate muscles, as well as the importance
of EMG or ultrasound (US) in this process [42].
2.2.3. Ultrasound-guided BoNT injections
In 46 patients with temporomandibular disorders, the anterior temporalis, anterior masseter,
deep masseter, anterior digastric, posterior digastric, and sternocleidomastoid muscles were
measured bilaterally by US with satisfactory visualization [49]. In clinical practice, however,
US guidance is not feasible for the pterygoid muscles and is only hardly feasible for the mimic
and pharyngeal muscles, probably because of their direct accessibility. Supra‐ and infrahyoid
as well as temporalis and masseter muscles can be visualized with US. However, guided BoNT
injection in this area is rarely necessary [50, 51].
2.3. Laryngeal dystonia (adductor and abductor spasmodic dystonia)
Spasmodic dysphonia (SD) is a rare form of focal dystonia—laryngeal dystonia [52]. It results
in irregular, uncontrolled contraction of the laryngeal musculature during phonation. SD is
task specific and typically affects connected speech. It can be subdivided, based on the clinical
signs and symptoms, into adductor, abductor, or mixed types [53].
The adductor type, caused by spasmodic activity of the vocal muscle (thyroarytenoid), is the
most common type affecting 80–90% of SD patients. It induces hyperadduction of the vocal
folds during speaking, producing a voice that is harsh, often tremulous, with inappropriate
pitch or pitch breaks, breathiness, and glottal fry [4, 54]. The abductor, a less common type, is
due to spasms of the posterior cricoarytenoid muscles (PCA), causing a prolonged, inappro‐
priate abduction of vocal folds during voiceless consonants. This results in a breathy, effortful,
hypophonic voice with abrupt termination of voicing and aphonic or whispered segments of
speech [4].
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BoNT/A, or BoNT/B, if there is resistance to type A, is considered the first‐line treatment for
SD [55]. Most investigators report a 75–95% improvement in voice symptoms and in quality
of life [4, 56]. Adverse events include transient breathy hypophonia, hoarseness and occasional
dysphagia, dyspnea, and stridor [57].
For adductor SD, the preferred treatment modality is the injection of BoNT into the intrinsic
adductor muscle compartment of the larynx that includes most often the thyroarytenoid and,
if a satisfactory effect was not observed, the lateral cricoarytenoid muscle as well [58]. Hillel
et al. (2004) suggested that interarytenoid muscle may be an active dystonic muscle and should
be treated in selected patients [59]. Treatment of abductor SD is challenging, because BoNT
injections into the PCA often results in only partial symptom relief. This may be due to
inaccurate placement into PCA. Meleca et al. (1997) described a transcricoid technique and
compared it with the standard retrocricoid approach in six patients. Both practitioners and
patients preferred the transcricoid method because of less discomfort, equivalent or better
voice results, and fewer side effects [57, 60]. For treating abductor SD, the cricothyroid muscle
can also be injected [4].
Unilateral or bilateral protocols have been proposed for treating both SD types [4, 61]. There
are a variety of injection approaches to deliver BoNT into the intrinsic laryngeal adductor
compartment, including EMG guidance, the ‘point‐touch’ technique, a transnasal or transoral
approach, and percutaneous fiberscopic guidance. No particular technique has been shown to
be superior to another [53, 62].
2.3.1. Anatomic/clinical muscle selection and localization of the injection needle
The ‘point‐touch’ technique is an injection method which relies on anatomical landmarks. It
is cheaper, quicker and more accessible, but has not yet gained widespread acceptance due to
concerns about patient satisfaction. In a prospective study of 37 patients with adductor SD,
post‐treatment results showed significantly improved swallowing [63]. A retrospective study
compared the effectiveness of BoNT injection between EMG‐guided and ‘point‐touch’
techniques in the treatment of adductor SD for a period of 8 years. No endoscopic guidance
or verification was utilized for injections using the ‘point‐touch’ technique, as based purely on
externally palpable laryngeal landmarks. Using a 1.5‐inch 27‐gauge needle, BoNT was
introduced percutaneously into the laryngeal adductor compartment. Adequate needle
positioning was guided by palpation and external landmark visualization alone. By the EMG‐
guided method a 37‐mm 27‐gauge monopolar, hollow‐bore, Teflon‐coated EMG needle was
inserted percutaneously into the area of the thyroarytenoid muscle with the most active motor
unit action potentials (MUAPs). There were no statistically significant differences in the rate
of effective injections (94.4 and 93.2%, respectively; p = 0.7), need to alter dose, breathiness, or
dysphagia. These results suggested that the BoNT treatment efficacy depends not only on the
injection method used but also on the experience of the physician [53]. It seemed that the ‘point‐
touch’ technique can be well tolerated by the patient. But it is a true blind technique and
visualization of the vocal folds may be required to confirm accurate placement of the needle
tip in the thyroarytenoid muscle [62]. Another version of the ‘point‐touch’ technique actually
represented an anatomic approach to BoNT injection that requires only a flexible nasophar‐
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yngeal endoscopy and careful evaluation of the anatomic landmarks. This technique has been
used successfully by Green et al. (1992) on 13 patients with adductor SD [64].
2.3.2. Electromyography-controlled BoNT applications
Experienced clinicians suggested that there are several unique instances in which needle EMG
guidance is necessary to achieve optimal results and avoid side‐effects, and one of them is the
percutaneous BoNT injections into vocal cords for the treatment of SD [14, 32]. It was even
thought to be the ‘gold standard’ for adductor SD treatment [63]. In a double‐blind treatment
trial of BoNT versus saline, laryngeal EMG‐guided injections into the thyroarytenoid muscle
were beneficial [65]. Several studies confirmed that BoNT transcutaneous injections under
EMG control into thyroarytenoid muscle represented a safe and effective treatment strategy
[64, 66]. The results obtained, however, did not suggest inferiority of other techniques of non‐
EMG guided laryngeal BoNT delivery [53]. In a retrospective study of 25 patients with
adductor SD, treated with EMG‐guided BoNT injection into the thyroarytenoid muscle,
substantial symptom relief was reported. However, a high percentage of side effects were
observed, although transient and mild — breathiness (68%) and choking on fluid (56%) [54].
Based on the evidence, laryngeal EMG was recommended as possibly effective for the injection
of BoNT into the thyroarytenoid muscle in the treatment of adductor SD [65]. A relative
drawback of the method might be the need for EMG confirmation of needle placement [64].
EMG‐guided BoNT injections are also used as a treating method in abductor type of SD. Blitzer
et al. (1992) reported 32 patients who have been treated by sequential percutaneous EMG‐
guided injections of the PCA muscles and improved to an average of 70% of normal voice. Ten
patients, however, required injection of the cricothyroid muscles and type I laryngoplasty [67].
A prospective randomized crossover trial compared two injection techniques—via either a
percutaneous posterior‐lateral approach (with EMG‐guidance) or an endoscopic (transnasal
fiberoptic) approach. Although patients perceived some benefits, blinded symptom counts did
not substantiate significant reductions in the numbers of breathy breaks occurred with either
techniques, and no differences were found between both techniques. Thus, BoNT/A injections
into PCA muscle provided limited benefits to patients with abductor SD, demonstrating the
need of a more effective therapy [68].
An advantage of EMG guidance is the confirmation of needle’s placement within the muscles
of the larynx by showing distinct MUAP with phonation, thus ensuring delivery of the exotoxin
into the most active portion of the muscle, near the motor end plate [62]. Using a non‐EMG‐
guided technique, placement of the needle into the vicinity of the muscle can be achieved, but
it is not possible to confirm placement into the most active portion of the muscle. It is ques‐
tionable whether BoNT needs to be delivered to the electrically most active portion, or if the
EMG signal is just an aid to direct the needle into the correct muscle. On the one hand, it is
assumed that more accurately placed dose in a particular muscle should reduce any side effects
in an adjacent muscle. On the other hand, it has been demonstrated that BoNT easily passes
through muscle fascia and can disseminate to the nearby muscles. It may be that once the
needle is in the vicinity of the correct muscle, toxin delivered will dose the entire muscle
regardless of needle tip proximity to the most active MUAP [53]. Some authors state that
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injecting by EMG guidance is more precise and uses the lowest therapeutic dose [69]. Cited
disadvantages include the possibility that EMG signal may be misleading, and the technique
is more time consuming, redundant to anatomic localization, or even more uncomfortable due
to additional needle positioning and manoeuvring. A few minor disadvantages to laryngeal
EMG‐guided BoNT administration may be related to a greater patient discomfort due to an
inherent longer period of needle placement during the search for MUAPs [53]. Some authors
suppose, however, that percutaneous injection with laryngoscopic guidance is less precise [69],
although there is not clear evidence to support the superiority of any particular localization
technique.
2.3.3. Endoscopy control
Although BoNT injection under EMG guidance is the standard for the thyroarytenoid muscle,
in some instances, endoscopy‐controlled BoNT placement could be an alternative [62]. Klap
et al. (1991) reported satisfactory effect of direct BoNT injections into the thyroarytenoid muscle
under fiberoptic visualization in six patients, followed for a period of 2 years [52]. In a
retrospective study, a total of 426 BoNT injections were administered in 64 adductor CD
patients under laryngoscopy guidance with satisfactory results, especially when BoNT
injection was placed at the posterior portion of the thyroarytenoid and directed towards the
lateral cricoarytenoid so that both muscle groups were affected [61]. A retrospective open trial
investigated the effect of toxin preparation and injection monitoring on 15 patients with
adductor SD. BoNT was administered into the vocalis muscle by 112 and 36 injections under
EMG or laryngoscopy guidance, respectively. Failure rate did not differ, using EMG (28.6%)
or laryngoscopy (30.5%) guidance. The treatment failure may occur regardless of the method
of injection, possibly due to mislocalization of the vocal folds [70]. Thirty patients with
adductor SD were randomly allocated into an EMG or a fiberscopy‐guided BoNT treatment
group. There were no significant differences in outcomes between the two groups in either the
duration of effectiveness or complications such as breathy voice and aspiration. BoNT injection
under fiberscopy guidance appeared to be a valuable alternative to EMG‐guided treatment in
adductor SD. The fiberscopy‐guided percutaneous injections have demonstrated high
reliability of confirming needle location. A source of discomfort may be the need of local
anaesthesia to aid the insertion of the fiberscope [62]. There is, however, limited number of
studies, comparing the endoscope‐controlled injection placement with other guidance
techniques, and additional investigations have to be performed in the field.
2.3.4. Ultrasound-guided BoNT injection
In laryngeal muscles, US guidance is hardly feasible. The laryngeal muscles (vocalis, PCA) can
be injected transorally using endoscopic guidance, or transdermally. For transdermal injection,
EMG guidance is crucial, either alone or, optionally, in combination with US [50].
2.4. Cervical dystonia
CD is the most common form of focal dystonia and is marked by deviation of the head around
horizontal (torticollis), coronal (retrocollis, anterocollis), and vertical axis (laterocollis), often
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associated with reduced range of motion in the direction contralateral to the movement.
Horizontal rotation is the most common abnormal movement, affecting 80% of the patients. It
typically arises from activity of the sternocleidomastoid muscle contralateral to the turn and
splenius capitis muscle ipsilateral to the direction of turn. Deeper muscles, including the
longissimus capitis, splenius cervices, longus capitis, and obliquus capitis, can also be in‐
volved. Laterocollis is seen in 10–20% and ipsilateral splenius, sternocleidomastoid, and
levator scapulae muscles are involved. Retrocollis and anterocollis are less frequent and
involve bilateral posterior and anterior muscles, respectively. Often combinations of torticollis
and laterocollis are presented. Shoulder involvement is present in approximately half of the
patients. Associated pain is reported in 70–75% [7].
BoNT is the first‐line treatment of idiopathic CD, and all commercially available BoNT brands
have proven satisfactory symptom relief in more than 85% of the cases [22, 32, 71]. Adverse
events are generally mild or moderate and transient, including pain at injection site, neck
weakness, flu‐like symptoms, hoarseness, dry mouth, and dysphagia. Systemic events include
general fatigue and muscle weakness [4].
The most injected muscles are the sternocleidomastoid, splenius capitis, trapezius descendens/
semispinalis capitis, trapezius horizontalis, levator scapulae, scalenii, and deep neck muscles
[30, 50].
2.4.1. Anatomic/clinical muscle selection and localization of the injection needle
In the large and easily accessible muscles, typically treated in CD, clinical placement seems
sufficient for the majority of patients [30, 32]. On physical examination, muscles should be
palpated for hypertrophy, activity and contracture, or fibrosis. Areas of pain should be noted
[30], as BoNT alleviates pain as well [72]. Manual application into the upper third of the
sternocleidomastoid muscle is often sufficient to reduce dysphagia considerably [50].
2.4.2. Electromyography-controlled BoNT applications
The majority of electrophysiological techniques applied for BoNT treatment of CD implied
polymiographic EMG for muscle detection and guidance of the injection needle [73]. Electric
stimulation (ES) is considered not to be feasible because the response of neck muscles to the
stimulus is not specific enough [74]. Only few EMG frequency analysis studies, with limited
number of patients enrolled, are advocating some benefits in targeting more specifically the
leading dystonic muscles [73]. The need of EMG guidance for CD patients remains an issue of
controversy [26]. Although superficial muscles that may be readily palpated are usually
involved, Barbano (2001) suggested that needle EMG exploration of the dystonic neck often
revealed affecting of deeper muscles which are difficult to access. Furthermore, muscles with
opposing actions are often in close proximity, making it possible to do more harm than good
with poorly targeted injections [75]. Several studies reported benefits of EMG‐guided BoNT
injections. Speelman and Brans (1995) showed the benefits of EMG guidance when the accuracy
of sternocleidomastoid localization in 139 EMG‐guided injections was examined. They found
that 83% of needle placement attempts reached the target muscles [76]. According to Wullf et
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al. (1993), the EMG guidance proved to be helpful as it restricted the injections into muscles
with EMG hyperactivity, thereby economizing the amount of toxin given. They conducted a
study of 20 idiopathic torticollis patients, who received EMG‐guided intramuscular BoNT/A
injections. An overall improvement of 55%, in comparison to the status before treatment was
found, and side effects were restricted to short‐term dysphagia in two patients [77]. Based on
the results of 84 patients, receiving injection under EMG guidance, Dubinsky et al. (1991)
revealed treatment effectiveness in 78.7%. The complications included excessive neck weak‐
ness, which was observed in 16.0% and dysphagia—presented in 11.1% of the injection
sessions [78]. Comella et al. (1992) randomized 52 CD patients into two groups. In the first one,
both clinical and needle EMG examinations were used for muscle selection, and injections were
performed by EMG assistance. In the second group, muscle selection was based solely on the
clinical examination and manual needle location. The EMG assistance did not increase the
number of patients improved, but the magnitude of improvement was significantly greater.
Moreover, in particular patients with retrocollis, head tilt, and shoulder elevation, additional
benefit with EMG‐guided BoNT injection were noted [79]. In a prospective study, Lee et al.
(2004) evaluated 15 CD patients. In those who underwent EMG‐guided BoNT injection, there
were fewer BoNT‐related side effects due to injection of the adequate dose to the accurate site
of hyperactive muscles. Besides, a greater clinical improvement due to confirmation of
hyperactivity in target muscles and a better ability to reduce the amount of oral medication
were reported. EMG‐guided BoNT injections were considered to be useful for patients with
retrocollis, for those who have had a suboptimal treatment response to non EMG‐guided BoNT
injections, and for those with increased concern of side effects or a concomitant goal of reducing
oral medications [80]. In a recent, one‐year prospective, randomized, and blinded study,
Werdelin et al. (2011) evaluated 20 CD patients, comparing EMG‐guided injections with
chemodenervation after clinical evaluation alone. Quantitative EMG was performed simulta‐
neously in the sternocleidomastoid muscles and the posterior neck muscles on both sides. In
patients treated on EMG guidance, clinical outcome, evaluated by objective ratings, was better
than in patients treated on clinical judgement alone. In a group blinded, 105 muscles were
injected with BoNT, but 37 of those did not show dystonic EMG activity. EMG guidance by
interference pattern analysis appeared to optimize BoNT treatment by more precise injection
localization and may reduce the amount of the toxin used, side effects, and the risk of devel‐
opment of antibodies [81].
Although the advantages of EMG‐guided BoNT application were reported, in most studies,
EMG was used not only for injection guidance but also for muscle selection. Due to that reason,
some authors advised that all these studies should be interpreted with caution [74]. A recent
review, focused on identifying the best method for muscle selection in CD patients, compared
EMG techniques with clinical examination and revealed that EMG‐guided injections may
improve the treatment outcome but did not show an overall better outcome compared to
clinical muscle selection and anatomical needle placement [73]. In the presented pooled
analysis of 28 studies of which 17 used clinical evaluation to identify dystonic muscles and 11
used EMG for selection and guidance, better results for the EMG approach regarding pain
reduction (−40.3 vs.−32.5 %) were recorded. However, improvement was lower for EMG
compared to clinical evaluation by rating scales like the Tsui score (−31.9 vs.−43.7%) [73].
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Some critical remarks also question the superiority of EMG‐guided injections in routine
treatment of CD. It has to be taken into account that positioning of the EMG needle is performed
according to anatomic landmarks. The placement of the EMG needle tip into a specific muscle
is thereby almost impossible to verify, as selective voluntary activation of neck muscles is not
possible and might be additionally superimposed by dystonic activity of adjacent muscles.
EMG therefore serves more as a ‘functional’ guidance than as an anatomical guidance. The
assignment of EMG activity to specific muscles is flawed by the same anatomic inaccuracy as
needle placement according to anatomical landmarks. Searching for dystonic EMG activity is
associated with additional discomfort and pain for the patients. It is more time‐consuming and
requires some extra costs [74]. Besides, needle EMG does not differentiate between contractions
produced by agonist versus antagonist muscles and may be misleading if the patient ‘tenses’
uninvolved muscles. If a muscle is obviously contracting or is hypertrophied, needle EMG is
redundant. A strong argument implies that if the results of BoNT treatment without needle
EMG are good, a small additional improvement does not justify the routine use of EMG [14].
On the other hand, based on clinical experience and an investigation of 20 CD cases, Cordivari
et al. (2006) suggested that if a patient started to respond poorly to BoNT/A and resistance to
the product was excluded, a re‐examination and careful placement of injections under EMG
guidance may improve the treatment outcome [82].
According to the Therapeutics and Technology Assessment Subcommittee of the American
Academy of Neurology, the role of EMG has not been established for CD [17]. It may contribute
for improving the outcome, especially in complex forms [32] or in secondary non‐responders
[82]. Still, evidence is limited and larger studies are needed [73].
2.4.3. Ultrasound-guided BoNT injections
Although BoNT/A has a favourable safety profile and is effective in the majority of patients
with CD, in some cases, the treatment outcome is disappointing or side effects occur when
higher doses are used. It is likely that in such cases either the target muscles were not injected
accurately or unintended weakness of non‐target muscles occurred [74]. Mezaki et al. (2000)
described an US investigation of cervical muscles for 20 dystonic patients compared with
healthy controls. They found contracting synergists responsible for the abnormal posture, a
finding not presented in healthy controls. The investigators suggested US to be an accurate
method for localizing the contracting muscles during injection, although the treating substance
used was not BoNT, but lidocaine and pure ethanol [83]. US is of special value as the injected
muscles differ in size, and the deep‐seated muscles require a different approach compared to
superficial ones [74]. Besides being a useful guidance, Mezaki (2011) suggested that it may be
even superior to the EMG monitoring, especially when the obliquus capitis inferior muscle is
targeted in rotatocollis, because the vertebral artery or upper cervical nerve root(s) may be
injured when the needle penetrates the muscle [72]. Dysphagia is a common side effect after
BoNT injections for CD, with an incidence of 10–40%, depending upon the study and dose
used. Hong et al. (2012) examined the effects on swallowing using EMG guidance for BoNT
injection and dysphagia occurred in 34.7%. Using US, combined with EMG guidance, there
was no dysphagia across 27 injection sessions, possibly because of retaining the injected toxin
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within the muscle [84]. Schramm et al. (2015) recently conducted a review of the relevance of
sonography in CD and provided a statement from clinical experts for its use. In the authors’
opinion, the routine use of US injection guidance could be recommended in general, as it
facilitates anatomically precise and reproducible injections in specific muscles. Ordinary
injected muscles are the splenius capitis, sternocleidomastoideus, semispinalis capitis, and
levator scapulae muscles, as well as more difficult accessible, small, or deeply located muscles
like the longus colli, longus capitis, scalene, and obliquus capitis inferior and superior muscles.
This method might prevent unintended muscle weakness due to diffusion of BoNT, bearing
in mind that injected neck muscles may be small or thin and lie in close proximity to each other.
US is also indispensable when case‐specific anatomic conditions are present such as obesity
or very pronounced neck muscles, or even muscle atrophy, occurring in consequence of
previous treatments. Furthermore, US helps in preventing injection in blood vessels and
nerves. This might be of special importance in CD as injections in lateral cervical muscles bear
a high risk for injuries of adjacent structures (carotid artery, thyroid truncus, internal and
external jugular vein, vagal nerve, phrenic nerve, and brachial plexus). With injections in the
dorsal neck region, the vertebral artery or the spinal canal may be erroneously injected.
Moreover, US guidance offers the potential for dose reduction. That may decrease the risk of
producing neutralizing antibodies and therefore ensure long‐term efficacy of treatment. The
combination of US and EMG could overcome the shortcomings of EMG regarding anatomic
precision and would allow an accurate assignment of dystonic activity to specific muscles [74].
However, as there are only a few small randomized studies suggesting superiority of sonog‐
raphy guidance compared to conventional needle placement, US guidance should be investi‐
gated in future clinical studies [50].
2.4.4. Positron emission tomography/computer tomography control
Herting et al. (2004) reported a case of a patient, suffering from severe anterocollis, where
repeated computer tomography (CT)‐controlled injections of BoNT into the right longus colli
muscle allowed a precise location of the needle and injection of the toxin, leading to an obvious
improvement of symptoms [85].
As it is well known that glucose metabolism and 18F‐FDG uptake are enhanced in contracting
skeletal muscles, it was suggested that the degree of 18F‐FDG uptake may be associated with
the strength of contraction. Moreover, an integrated positron emission tomography/computer
tomography (PET/CT) controlled method was found to provide both metabolic and anatomic
information on hypermetabolic lesions [86, 87]. Sung et al. (2007) investigated six patients with
idiopathic CD. BoNT injections into target muscles were performed with Teflon‐coated
monopolar needle electrode cannula guided by EMG. For deep cervical muscles adjacent to a
major artery or the major nerve trunk (obliquus capitis inferior and longus colli muscles), BoNT
was injected under CT or US guidance. All four patients who underwent PET/CT‐guided
injections experienced a significant improvement in symptoms, even though in three of these
patients, previous BoNT therapy guided by clinical findings had failed [87]. Similar results
were obtained by Lee et al. (2009), who conducted a study with 14 BoNT treated CD patients
and compared different localization techniques. Muscles for BoNT injection were selected after
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considering abnormal posture type and EMG, and PET/CT findings. When selected muscles
were located beyond the expected coverage of the EMG needle, near an important structure,
imaging‐guided injection was considered. A total of 13 BoNT injections in eight patients were
performed under imaging guidance, and technical success was achieved in all cases. For
injections into the longus colli muscle (poor sonic window due to the pharynx), the obliquus
capitis inferior muscle, and the scalenus anterior, scalenus posterior, and levator scapulae
muscles, CT guidance was chosen. Otherwise, US guidance was preferred because of its
convenience. The results obtained using PET/CT and imaging guidance were superior to
results obtained on the basis of physical examination or EMG [71]. Although CT provides a
precise visualization of deep muscles of the neck and the surrounding structures, a disad‐
vantage of the method is that its use is limited to a clinical setting where CT is accessible.
Therefore, the use of CT has been recorded in a small number of patients. Moreover, CT is too
expensive for frequent use in daily practice, it is not dynamic, and patients are exposed to
radiation [50, 74].
PET has been used in two studies (mentioned above) to identify hypermetabolic and presum‐
ably dystonic muscles, whereas injection was performed under CT or US guidance [71, 87].
PET, therefore, rather represents a diagnostic method and not a method for injection control
[74].
2.4.5. Fluoroscopy (electromyography combined with fluoroscopy)
While BoNT is the treatment of choice for CD, patients with anterocollis, who receive injections
into the sternocleidomastoid and anterior scalene muscles, present a disproportionate number
of treatment failures. Incomplete muscle selection may be one cause of treatment failures in
anterocollis. Deep cervical muscles, such as the longus colli, are not routinely injected. Glass
et al. (2009) described a technique for longus colli injection in three cases of anterocollis and
reported the clinical outcomes of 10 such BoNT injections. The patients had previous treatment
failures with sternocleidomastoid/anterior scalene injections or no activity was recorded
during the needle EMG investigation of these muscles. All patients were injected into the
longus colli under fluoroscopic and EMG guidance, which resulted in a significant sympto‐
matic improvement (8 of 10 injections). Two patients reported mild dysphagia without serious
complications after dose increased. It seems that fluoroscopic guidance allows safe and
effective BoNT injections into deep cervical muscles [88]. However, fluoroscopy is associated
with the application of considerable amounts of radiation and multiple intramuscular
injections of iodinated contrast media, both of which can be potentially harmful [50].
2.4.6. Magnetic resonance imaging control
Magnetic resonance imaging (MRI) allows high‐definition visualization of deep muscles, such
as the longus colli and obliquus capitis inferior, glandular tissue and critical structures.
Mixtures of BoNT and contrast medium allow documentation of the toxin placement. How‐
ever, the visualization is not in real time, so that the relationship between the injection needle
and the target tissue cannot be monitored continuously. Other disadvantages including costs
and time prevent the routine use of this method [50].
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2.5. Limb dystonia
Focal upper limb dystonia usually starts in the hand and is task specific; however, with
progression, task specificity is gradually lost [89]. Other occupational hand dystonia and
nontask‐specific (fixed) dystonia are presented mainly by writer’s cramp [17]. The upper
extremity is affected more commonly than the lower, and most BoNT studies deal with the
upper limb, and especially with writer’s cramp [17, 18]. Writer’s cramp is a task‐specific
dystonia characterized by involuntary, repetitive, or sustained contractions of finger, hand, or
arm muscles that occur during writing and produce abnormal postures or movements that
interfere with normal handwriting [90]. Injections for writer’s cramp are usually focused on
finger flexors and extensors in the forearm, but wrist pronators and flexors are often involved
[18].
Foot dystonia is often presented with foot inversion, toe dorsiflexion, and/or ankle plantar
flexion. The injected muscles may include tibialis posterior, extensor hallucis longus, gastro‐
cnemius, and long toe flexors. Usually the treatment requires higher dose of the neurotoxin [4].
BoNT remains the first choice treatment, as there are no effective alternative medical or well‐
established surgical therapies. It is recommended as probably effective for treatment of focal
upper extremity limb dystonia. BoNT treatment is considered to be possibly effective for lower
extremity dystonia, but the presented data are insufficient to provide a recommendation [17,
91]. Therapeutic difficulties occur due to involving the subtle tuning of many muscles. Besides,
it is difficult to obtain the requested quality of voluntary movement without weakness. Pain
is the symptom most frequently improved, often independently of motor function [4]. In case
of neutralizing antibodies against the A toxin, the treatment with BoNT/ B or BoNT/F is a
possible alternative [32, 92]. The use of BoNT to treat limb dystonia requires thoughtful
technique including customization of doses and muscle selection. The first step in treatment
planning is to identify the muscles most severely affected, separating out dystonic from
compensatory movements. After initial inspection, EMG‐ or US‐guided muscle selection
usually allows refining the choice of targets [89].
2.5.1. Anatomic/clinical muscle selection and localization of the injection needle versus
electromyography-controlled BoNT applications: passive and active electromyographic guidance
As focal hand dystonia is a complex disorder, usually involving several muscles, and many of
them are deep, not easily identified by surface landmarks and not palpable on examination,
their localization is often challenging [50]. In some instances, however, physicians use their
knowledge on surface anatomy and clinical examination to localize the target muscles but
EMG guidance may be particularly important. In a trial, 40 patients with writer’s cramp were
randomized in a double‐blind design to BoNT or an equivalent volume of saline placebo.
Injected muscles were chosen based on clinical examination, but injections were performed
under EMG guidance and a significant improvement was obtained [90]. In a prospective,
double‐blind crossover study of 17 patients with upper and lower limb dystonia, target
muscles were identified either clinically on the basis of the abnormal posture and muscle
contraction or by EMG guidance. The EMG method allowed the patient to perform the task
that precipitated the cramp while EMG activity was recorded. Clinical and EMG identification
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usually correlated well, but on some occasions, muscles identified by clinical evaluation were
not regarded as abnormal by EMG and vice versa. Received injections were EMG guided.
Using a patient subjective scale, 82% reported benefit; however, physician rating did not reveal
significant difference in the treatment outcome. The main side effect was focal weakness that
emerged after 53% of BoNT injections [93]. In another placebo‐controlled, double‐blind,
crossover trial in 20 patients with writer’s cramp, muscle selection was determined by clinical
examination. In eight patients, however, EMG was employed to guide selection of muscles.
Twelve patients had improvement in pen control, but only four had significant improvement
in writing. Focal weakness was the only adverse event and was severe enough to worsen pen
control in one patient [94]. Molloy et al. (2002) compared the efficacy of EMG‐guided versus
non‐guided injections for limb dystonia in a randomly chosen cohort of 14 consecutive patients.
Only 37% of needle placement attempts reached the proper muscles in the absence of EMG
guidance. Forty‐seven percent were placed in an unintended muscle or fascicle and 16% were
outside the muscle altogether. Individual finger fascicles of larger muscles such as flexor
digitorum profundus or extensor digitorum communis were particularly difficult to isolate
accurately without EMG [95]. EMG recording during the task associated with dystonia may
be helpful to pinpoint muscle activation patterns [18]. Schuele et al. (2005) demonstrated
benefits of EMG guidance in a study of 84 musicians with focal task‐specific dystonia, treated
with EMG‐guided BoNT injections, where 69% of the patients experienced improvement from
the injections and 36% reported a long‐term benefit in their performance ability [96]. Sojer et
al. (2001) even suggested that BoNT treatment of writer’s cramp required EMG‐guided
injections in order to avoid side effects [32]. Because of the numerous small muscles located in
a close proximity, some authors give priority to an active EMG muscle selection and needle
localization, namely ES. It may be applied when a common muscular origin and innervation
of different adjacent muscle exist, as with the extensor digitorum, flexor digitorum sublimis,
and profundus. In such cases, passive EMG guidance appeared to be less useful, as it is difficult
to flex or extend these digits without also causing similar movement in the adjacent ones.
However, BoNT may spread to adjacent sites by diffusion, even with use of increasing target
accuracy‐guiding techniques [12]. Barbano (2001) also recommended ES for upper extremity
dystonia, where an inappropriate toxin placement can worsen the functional outcome by
weakening non‐dystonic adjacent muscles, or in cases where it is important to weaken
particular fascicles of individual muscles. Moreover, ES ensures the proper localization in
sedated patients or in those who otherwise would have difficulty with fine motor control, such
as children [75]. Due to the lack of consensus on the best way to localize muscles in the forearm
for BoNT injection, Greenen et al. (1996) conducted a study comparing EMG with ES in 12
patients with the conclusion that localization by stimulation is probably at least as good as
EMG. Weakness of ‘non‐target’ muscles was present with both techniques [97]. In a critical
expert review, based on long‐term experience, Jankovic (2001) concluded that there are several
unique instances in which needle EMG guidance is essential to achieve optimal results. These
include BoNT treatment of certain task‐specific dystonias, like in keyboard and string musi‐
cian’s cases, that are particularly difficult to treat because accurate and well‐coordinated hand
and finger movements are involved. However, even in patients with occupational cramps, such
as dystonic writer’s cramp or focal hand tremor, an injection into the forearm flexor muscles
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(e.g., flexor carpi radialis and flexor carpi ulnaris) could be successfully performed by using
well‐defined anatomic landmarks. Benefits were obtained from local BoNT injections in
patients with dystonic writer’s cramp that were similar to the benefits seen when using
complex EMG and fine‐wire electrodes to localize bursts of muscle activation during the task
and by injecting the toxin through a hollow EMG needle into the belly of the most active
muscle [14, 98]. Therefore, if there is a minimal increase in improvement, the routine use of
the EMG‐guided approach does not justify the increased discomfort, time, and expense of this
method, as compared with clinical examination. Moreover, it is known that BoNT diffuses
outside of the target muscles even when these muscles are localized by ES [14].
In one series of patients with upper limb dystonia, weakness of uninjected muscles, adjacent
to the injected, was found in 63% of the patients which was the primary cause of a suboptimal
response in 15% of them [99]. The treatment of focal limb dystonia with BoNT is challenging,
particularly in achieving sufficient neuromuscular blockade to alleviate dystonic movements
without causing excessive muscle weakness. While many clinicians advocate EMG or ES to
optimize needle localization for injection, further data are needed to establish this recommen‐
dation [17].
2.5.2. Ultrasound-guided BoNT injections
Active EMG guidance or US guidance (or a combination of both) has been found to be most
helpful when targeting the forearm muscles especially for task‐related dystonia [100]. In many
patients with writer’s cramp, the BoNT dose could be reduced when switching from manual
application to US guidance [50]. US is feasible for proximal and distal arm muscles, intrinsic
hand muscles, and leg muscles. For forearm and leg muscles, US visualization may protect
sensitive adjacent structures (nerves, large vessels). The usefulness of US is low, however, in
shoulder, proximal arm, and superficial axial muscles, because of their size and accessibility
[50].
3. Spasticity
Central nervous system disorders with upper motor neuron dysfunction often produce
spasticity and hypertonia of the limb that is dependent both on velocity and on range of motion.
Besides increased tone, spasticity presents typically with increased muscle stretch reflexes,
muscle spasms and clonus, weakness (spastic paralysis), and impairment of voluntary
movements. Spasticity may occur in diffuse or focal pathological disorders of the brain and
spinal cord. In adults, spasticity results from diverse aetiologies, including stroke, traumatic
brain injury, multiple sclerosis, and neoplasm involving the central nervous system. The most
common cause of spasticity in children is cerebral palsy (CP) [4, 18, 101]. In the upper extrem‐
ities, the shoulder adductors, elbow flexors, wrist pronators, finger, and thumb flexors are
frequently involved. In the lower extremities, hip adductors, knee extensors, and ankle plantar
flexors and inverters may have increased spastic tone [18].
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Treatment is aimed at prevention of contractures and improved functional outcome, without
worsening weakness. Non‐pharmacologic treatment options often do not provide long‐term
relief, and systemic interventions can have intolerable side effects [102]. BoNT efficacy is better
established for spasticity in the upper rather than lower limb [4, 18]. BoNT doses used in
spasticity are higher than those used in other movement disorders. The treatment effect is
maintained for approximately 3–5 months [4]. Adverse events are rare, often benign and of
short duration, as the majority of the self‐reported adverse events include local muscular
weakness or fatigue [103].
Several localization techniques are available to physicians that allow identification of the
selected target muscles. These methods include anatomic localization in isolation or in
conjunction with EMG guidance, ES guidance, or US guidance [102].
3.1. Anatomic/clinical muscle selection and localization of the injection needle
BoNT/A injections given by manual intramuscular needle placement in the lower extremity
under general anaesthesia is an established treatment and standard of care in managing
spasticity in CP children [104]. Most clinicians do so using manual technique without radio‐
logic or EMG guidance to aid needle placement [105, 106]. This procedure is usually performed
by finding the largest bulk of the muscle and injecting the toxin into several sites at mid‐belly
[105]. In a placebo‐controlled, double‐blind, randomized multicentre study, Mall et al. (2006)
evaluated BoNT/A effect on adductor spasticity in 61 CP children, concluding that in large and
easily accessible muscles, that are typically treated in adductor spasticity, clinical placement
seems sufficient for the majority of patients [107]. However, Chin et al. (2005) investigated the
accuracy of the ‘free hand’ intramuscular needle placement guided by anatomic landmarks,
palpation, and passive stretching of the muscles with ES‐guided method for upper and lower
limb spasticity in 226 CP children. The accuracy of manual needle placement compared with
ES was acceptable only for the gastrocnemius and soleus muscles (75%). It was unacceptable
for all the other muscles investigated—the hip adductors (67%), medial hamstrings (46%),
tibialis posterior (11%), biceps brachii (62%), and forearm and hand muscles (13–35%). The
authors recommended using ES or other guidance techniques to aid injection preciseness [106].
In a prospective study, the accuracy of manual needle placement of 272 injections in gastro‐
cnemius muscles of 39 children with spastic CP was checked against US. The needle was
accurately inserted into gastrocnemius muscles in 78.7% of the cases. Accuracy was acceptable
for gastrocnemius medialis (92.6%), but not for gastrocnemius lateralis (64.7%) [108]. A
randomized controlled trial compared the efficacy of BoNT/A injection guided by ES or
palpation, and 2 weeks of physiotherapy, to treat spasticity of the ankle plantar flexors in 65
children with spastic CP. The ES‐guided injection group plus physiotherapy showed greater
improvement in the spasticity and functional performance, than the other two groups (the
BoNT/A group guided by palpation injection plus physiotherapy and the physiotherapy‐only
group) [109]. Some critical evaluation of the largest studies applying manual needle placement
in the spastic lower extremity of CP children was performed. Warnink‐Kavelaars et al. (2013)
pointed as a main disadvantage of the studies the lack of a standardized injection protocol,
which interfered with a correct base for accurate statistical analysis. Besides, methodological
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methods used did not allow the calculation of positive and negative predictive values,
sensitivity, and specificity, which obscured the outcome [104]. Thus, Warnink‐Kavelaars et al.
(2013) developed a detailed protocol for manual intramuscular needle placement checked by
passive stretching and relaxing of the target muscle (PSRM). It was developed for each
individual muscle injection location of the adductor brevis, adductor longus, gracilis, semi‐
membranosus, semitendinosus, biceps femoris, rectus femoris, gastrocnemius lateralis,
gastrocnemius medialis, and soleus muscles. PSRM is a rapid intramuscular needle localiza‐
tion technique, useful for larger muscles, especially in the lower extremity, which can be
performed without sophisticated equipment. Manual intramuscular needle placement would
be assessed as a PSRM‐positive verification when the needle moves upon passive stretching
and relaxing of the intended muscle, or a PSRM‐negative verification when there is no
movement or only a small straight motion of the needle upon passive stretching and relaxing
of the muscle. This needle location protocol would be verified then by means of ES [104].
Several clinical trials compared the efficacy of BoNT treatment in adults with spastic upper or
lower limbs, when injections were placed only by clinical and anatomic landmarks, with those
guided by ES or US. Still, Childers et al. (1996) suggested researches comparing more precise
localization methods for BoNT/A injections might further establish the importance of EMG
guidance [110]. A very recent randomized controlled study compared manual needle place‐
ment with ES‐ and US‐guided techniques for BoNT injection of 60 adults with arm (wrist and
finger) spasticity. One month after injection, the outcome measurement instruments used
revealed greater improvement in the ES group than in the manual needle placement group.
Furthermore, patients improved more in the US group than in the manual needle placement
group. No difference was found between the US and the ES groups. These results implied that
instrumental guidance may improve the outcome of BoNT injections into the spastic forearm
muscles of stroke patients [111]. Another recent controlled trial compared the three localization
techniques, mentioned above, but this time for the gastrocnemius of adults with spastic
equinus after stroke. Forty‐seven patients were randomized into three groups, and each patient
received the same dose of BoNT/A into the lateral and medial head of the gastrocnemius
muscle of the affected leg. One month after injection, the modified Ashworth scale recorded
greater improvement in the US group than in the manual needle placement group. The ankle
passive range of motion improved better in the US group than in the ES and the manual needle
placement groups. No difference was found between groups for the Tardieu scale. A superi‐
ority of the US‐guided injection technique was shown and the authors concluded that it could
improve the clinical outcome of BoNT injections into the gastrocnemius of adults with spastic
equinus [112]. Henzel et al. (2010) also compared US localization with surface landmark
localization of BoNT injection targets for forearm muscle spasticity in 18 patients. Flexor
pollicis longus, flexor carpi radialis, pronator teres, and flexor digitorum superficialis were
identified by these separate localization techniques. Significant differences were observed
between surface and ultrasound proximodistal and lateral coordinates for several flexor
muscles. It seemed that US could improve the accuracy of toxin placement and help to avoid
injection into vascular and nerve structures, so that it should be considered as an adjunct for
localization in patients with upper limb spasticity [113].
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Schnitzler et al. (2012) evaluated the accuracy of manual needle placement in the gastrocnemius
muscles guided only by anatomical landmarks and palpation. One‐hundred twenty‐one
practitioners were evaluated. Fifty‐two injections were successful (43%) and 69 failed (57%),
showing a poor success rate, regardless of the injector experience. Therefore, muscle palpation
and anatomical landmarks were insufficient to ensure the accuracy of BoNT/A injections, even
for large, superficial muscles [114]. In clinical practice, however, clinical landmarks and
palpation are still often used for injecting superficial limb muscles.
3.2. Electromyography-controlled BoNT applications
The use of EMG or the motor point stimulation method is recommended to identify muscles
targeted for injection, particularly for the smaller muscles in the forearm and hand [105].
Several case series and small studies reported a satisfactory treatment outcome when identi‐
fication of the target muscles in the affected hand and forearm of post‐stroke adults was made
by passive EMG that was used also to guide the injection needle [115–117]. However, EMG
was successfully applied also in the BoNT treatment of large, superficial, as well as deep
muscles in the lower extremity. Statistically significant improvement in gait parameters were
noted in the treatment of 12 chronic hemiparetic patients with pronounced lower limb extensor
spasticity. The soleus, tibialis posterior, and gastrocnemius muscles of the affected side were
injected using a 21‐gauge Teflon‐coated needle, which was also used as an EMG electrode.
Injections were made at two sites close to the motor point, which was identified by standard
neurophysiological techniques. The toxin was injected only when either a continuous or
stretch‐induced EMG activity was recorded, otherwise another injection site in the vicinity was
checked [118]. An open BoNT/A effectiveness study comprised 40 patients, with moderate to
severe spasticity of the upper (13) or lower limbs (27) refractory to conventional physical and
medical treatments. To ensure precise muscle selection, the authors localized the target muscle
primarily on clinical assessment, and after that recorded muscle activity using EMG and
injected targeting the middle third of the muscle belly. The initial dosage of BoNT/A varied
with individual muscles and the degree of their involvement as judged clinically and as
confirmed by EMG. Thirty‐four patients (85%) derived worthwhile benefit, with improved
limb posture and increased range of passive motion in 31, pain reduction in 28 of 31 with pain,
and improved function in 16. Side effects were limited to local and usually mild discomfort
from the injections (19), symptomatic local weakness (1), and local infection (1) [119].
Active EMG guidance may be applied when treating spasticity, where it is difficult to accu‐
rately target the muscle using voluntary contraction. Following injection, however, BoNT may
spread to adjacent sites by diffusion, even with the use of special guidance techniques to
increase the accuracy of targeting [12]. Quantitative EMG criterion (turn/amplitude analysis)
may also be a valuable tool for selection of target muscles, determining benefits of single and
subsequent BoNT applications in the treatment of spasticity [120].
In CP children, several studies reported some benefits from BoNT injections after ES localiza‐
tion of appropriate muscles [121, 122]. ES is easy to perform, does not require formal EMG
training, and does not prolong the procedure significantly [105]. Although the passive [123]
as well as the active EMG‐guided techniques have shown to be more accurate in needle
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placement than the manual technique, they are of limited use in children because the procedure
is painful [124] and time‐consuming, and requires the cooperation of the patient. Thus, it does
require the patient to have sedation or mask anaesthesia. However, these techniques are used
in needle placement, but it remains uncertain whether the effort to improve the BoNT injection
accuracy would lead to a better response to the toxin [105].
In general, it seems that the importance of EMG or ES for guiding BoNT injections in limb
muscles to treat dystonia or spasticity appeared to be based more on theoretical and preclinical
data than on controlled clinical trials. Questions remain about the preferred administration of
BoNT for these conditions. Future clinical researches are necessary to demonstrate a clear
functional benefit of any particular injection localization method [125].
3.3. Ultrasound-guided BoNT injections
As BoNT/A is a first‐line treatment for post‐stroke focal spasticity, and the accuracy in
delivering the toxin to the target muscles may influence the treatment outcome, a randomized
clinical trial compared the reduction of upper limb spasticity using US guidance and manual
needle placement (two groups of 15 stroke patients each). After one month of follow‐up, the
scores of the modified Ashworth scale and the finger position at rest were significantly
improved in both treatment groups, although these clinical outcomes were significantly better
in patients treated under US guidance [126]. In the above‐mentioned randomized controlled
study, manual needle placement was compared to ES‐ and US‐guided BoNT injections into
spastic forearm muscles and both US‐ and ES‐guided techniques revealed better results than
manual needle placement, but no difference was found between the two instrumental guided
groups [111]. Henzel et al. (2010) compared US localization with surface landmark localization
of BoNT injection in the forearm muscles in 18 spasticity patients and significant differences
were observed between surface and ultrasound proximodistal and lateral coordinates for
several flexor muscles, assuming that ultrasound can improve accuracy of toxin placement
[113]. Another controlled trial (described more detailed above) compared manual needle
placement versus ES and US guidance, but this time for the gastrocnemius muscle with better
results obtained in the US group than in the ES and manual needle placement groups [112].
Ding et al. (2015) very recently explored the effectiveness of colour Doppler US‐guided BoNT/
A injection combined with an ankle foot brace for treating lower limb spasticity after a stroke.
They found that the colour Doppler US‐guided BoNT/A injection could be a safe and precise
technique and a useful adjunct to the ankle foot brace treatment method [127]. US feasibility
is intermediate in superficial leg muscles. It is high in forearm muscles, intrinsic hand muscles,
and deep leg muscles, unless spasticity is massive and functionality is not an issue [50].
As the US‐guided BoNT injection technique is easy, quick and painless, many authors
suggested it might be a suitable method for use in children [105]. Moreover, according to the
European consensus statement, children with CP should generally receive BoNT injections
using EMG guidance or US guidance [128]. Kown et al. (2010) recently compared the clinical
outcomes of ES‐ and US‐guided localization techniques for BoNT/A gastrocnemius injections
for the treatment of spastic equinus in CP children. Subscales of the physician’s rating scale
significantly improved in the US‐guided group, but no statistical differences were noted in the
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modified Ashworth scale, the modified Tardieu scale, and the selective motor control. Ac‐
cording to the authors, visual feedback by US could improve the accuracy of selective neuro‐
muscular blocking of the gastrocnemius [129]. Besides, this guidance is preferable in children
due to a better tolerability [50]. Another study compared manual needle placement with US‐
guided technique for BoNT injections into affected lower extremities in CP children. For the
lower limb spasticity, the deep‐located tibialis posterior muscle, although potentially difficult
to inject, needle insertion is often performed using anatomic landmarks for guidance. Accord‐
ingly, the US anatomy of the lower leg was investigated in 25 subjects. B‐mode, real‐time US
was performed using a 5 – 12 MHz linear array transducer. During anterior and posterior
approaches, safety window width and depth were measured at the upper third and at the
midpoint of the tibia. Considering the safety window width, this study suggested needle
placement at the upper third of the tibia for the anterior approach and at the midpoint for the
posterior approach to be safe and useful in BoNT injections [130].
US guidance of BoNT injections, however, was not solely used for limp spasticity. Chen et al.
(2010) aimed to evaluate the effects of a single transrectal US‐guided transperineal injection of
BoNT/A to the external urethral sphincter for treating detrusor external sphincter dyssynergia
in 18 patients with suprasacral spinal cord injury. There were significant reductions in
integrated EMG and static and dynamic urethral pressure, but not in detrusor pressure and
detrusor leak‐point pressure after treatment. Postvoiding residuals also significantly de‐
creased in the first and second month after treatment. The technique had beneficial effects in
treating detrusor external sphincter dyssynergia [131]. Later on another study compared the
results of a transrectal US‐guided BoNT injection (18 cases) with those of a cystoscopy‐guided
method (20 cases) to the external urethral sphincter. Although there were no significant
differences between the groups in all of the outcome measures, the study demonstrated that
transrectal US‐guided transperineal BoNT injection may be an alternative to a cystoscopy‐
guided injection. This alternative procedure provided clinicians with an innovative and less
invasive method that is performed without requiring anaesthesia or cystoscopy [132]. In a non‐
controlled clinical trial on 19 men with sphincter hypertonia due to spinal cord injury, BoNT
was injected through the transperineal way in the external urethral sphincter under EMG and
transrectal US guidance, and that appeared to be an effective and safe therapeutic option [133].
It appears that although at present it is not possible to identify a golden standard among
injection techniques, US guidance may be very useful in precise targeting of injections, and
may help to avoid BoNT application into fat, fibrosis, vascular, and nerve structures, mini‐
mizing the spread of the toxin outside the targeted muscle belly, thus improving clinical
outcomes [126]. As it is a non‐invasive method, providing a relatively quick and painless
muscle selection, the US‐guided BoNT injection has been recommended as a standard
procedure in treatment of lower leg spasticity in children with CP [50].
3.4. Endoscopy control (esophagoscopy and electromyographic guidance)
Since dysphagia and deglutition problems combined with aspiration are often caused by
spasticity, hypertonus, or delayed relaxation of the upper esophageal sphincter, Schneider et
al. (1994) replaced the conventional treatment including lateral cricopharyngotomy by
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localized BoNT injections into the cricopharyngeal muscle in a series of seven patients. For
precise localization, injections were performed under general anaesthesia after location of the
cricopharyngeal muscle by direct esophagoscopy and EMG guidance. Injections were admin-
istered into the dorsomedial part and on both sides into the ventrolateral parts of the muscle.
All but two patients experienced complete relief or marked improvement of their complaints.
There were no severe side effects or postoperative complications. This method seemed to be
an effective alternative treatment to invasive procedures for patients with isolated dysfunction
of the upper esophageal sphincter, and also for patients with more complex deglutition
problems combined with aspiration [134].
3.5. Magnetic resonance imaging/computer tomography/fluoroscopy
MRI-, CT-, and fluoroscopy-guided procedures are typically performed by interventional
radiologists [101, 135]. Because most clinicians who perform BoNT injections are not typically
radiologists, US guidance of the injection is the imaging localization method routinely used.
Moreover, it has several advantages in comparison with the other imaging methods, including
lack of radiation, low cost, and higher accessibility, whilst providing comparable results with
the mentioned imaging guiding techniques [50, 74].
4. Summary
All the studies reviewed in this chapter were quite heterogeneous regarding the characteristics
of subjects and dosage, study methodology, clinical outcome measurements, and these
differences hinder the possibility of performing an exact comparison or statistical analysis.
Most of the studies either exploring an injection localization technique or comparing different
guiding methods enrolled a small number of patients that did not allow a general unflinching
recommendation to be made. The heterogeneity of muscles affected by dystonia or spasticity
also contributes to the latter. However, there were some randomized, controlled clinical trials
presented, but the most frequent conclusion was that there is still need of more studies in the
field, so that a solid proof of the superiority of a certain localization method for BoNT injection
in each specific condition can be offered.
There is informal agreement on the practicalities of BoNT injections for dystonia. The clinical
examination is the simplest and most commonly applied method for localization of an
overactive muscle. Based predominantly on palpation and surface anatomy, the clinical
examination is usually sufficient to target a superficial muscle when not lying in close prox-
imity to antagonistic muscles, such as most facial and some cervical muscles. Thus, it is
routinely applied in the treatment of blepharospasm, some types of CD, and in many JCDs [4,
26, 106]. In these regions, EMG and imaging-guided targeting provide a second-line approach
whenever refinement of muscle selection is needed or when treating a complex form [4, 71].
Although it might be beneficial, EMG is not necessary for large, superficial, easily visible
muscles but is advisable for smaller and deep muscles, not readily accessible to palpation [18].
This would be the case of SD and JOD [26]. In the case of some task-specific dystonias, EMG
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guidance is believed to provide optimal treatment results [14]. Barbano (2001) pointed that the
main advantage of needle EMG guidance is precision of toxin placement, which allows a lower
dose to produce an equivalent effect. Furthermore, lower toxin doses will decrease the chance
of developing neutralizing antibodies and may also allow the injection of more muscles in
patients with more widespread disease [75]. However, passive EMG guidance requires
selective activation of the target muscle, which is difficult to perform for patients with higher
degree disturbances. In patients with dystonia and sometimes also in patients with spasticity,
the co‐activation of adjacent muscles may superimpose the target muscle activity. EMG
guidance may be improved by ES via the injection electrode [50]. ES is the technique of choice
when attempting to precisely target small muscles sited adjacent to muscles for which no BoNT
effect is desired, as it is in the forearm and foot muscles. Passive EMG guidance is preferably
used when injecting patients with CD or SD [12]. The disadvantages of EMG guidance include
increased discomfort due to larger size of EMG needles and the lack of identification of critical
structures, such as nerves and vessels and the lack of control of the applied BoNT [50].
Moreover, needle EMG is relatively invasive and may cause complications, such as bleeding
and infection, and presents electrical hazards [87]. Jankovic (2001) pointed that if there is an
obvious benefit of non‐guided EMG BoNT treatment, a small additional improvement does
not justify the routine use of EMG [14]. It is presumed that quantitative EMG‐guided injections
of BoNT for OMD and CD may provide treatment benefits, but very few studies, exploring
the methodology, are available [46, 73]. Surface recording electrodes have been used in some
trials but their recordings are limited to superficial muscles. Fine‐wire electrodes have also
been used, mainly for simultaneous recordings of several muscles. All these techniques are
more appropriate in the research setting [26].
Recently imaging‐guided BoNT injections become more popular and practiced. B‐mode US
allows immediate and high‐resolution imaging of the injection needle position within the
target region. Visual identification of muscles and depth control of needle placement are the
key features of US‐guided injection that lead to improved targeting and safety of BoNT
applications [50, 74]. Some physicians also used the color Doppler technique in addition to the
real‐time B‐mode scanning in order to visualize more accurate adjacent blood vessels. An
emerging application is the US‐guided BoNT injection into deep cervical and nuchal muscles
in patients with CD, such as the scalene muscles, the longissimus cervicis muscle, and the
obliquus capitis inferior muscle [50]. The use of US for locating both superficial and deep
muscles is growing, as it is safe, non‐invasive, and less distressing than EMG. US guidance is
extremely useful when injecting muscles, adjacent to large blood vessels, or nerves, as is the
case with deep cervical, forearm, and leg muscles injections [18]. The method, however, is not
feasible for the pterygoid muscle and hardly feasible for the most mimic, pharyngeal, and
laryngeal muscles.
Other imaging techniques, including CT or PET/CT, MRI, and fluoroscopy, are used to help
accurate selection when affected muscles are deeply located (as with CD); however, these
techniques are of limited value due to high costs, radiation exposure, or non‐availability in
daily clinical routine [71, 74].
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Endoscopy‐controlled BoNT injections in the terms of fiberscopy or laryngoscopy, for the
treatment of SD, or as esophagoscopy in spasticity, may lead to a satisfactory treatment
outcome, but often require a multidisciplinary approach that limits to some extend its use in
the clinical practice [62].
Manual needle placement is still often applied in the BoNT treatment of limb spasticity. It might
be sufficient in some instances when targeting large and easily accessible muscles [107],
although contradictory data exist, suggesting poor success rate [114]. Thus, most studies in
this area deal with electrophysiological or US techniques to optimize muscle localization for
injection. Another common approach is to perform ES or EMG targeting. Similarly to focal
limb dystonia, EMG is advisable for smaller and deep muscles, and it is particularly applicable
in forearm and lower leg muscles and hip flexors (psoas major) [18]. Due to the listed advan‐
tages, US is considered as a valuable adjunct for muscle localization in patients with spasticity
and could improve the accuracy of BoNT placement, as well. Moreover, US is already widely
applied in neuropaediatric care for CP patients, as it was associated with less pain [74].
The preference of a specific localization BoNT injection method also depends on the clinical
expertise of the performer, the profound knowledge on anatomy and clinical landmarks, as
well as the experience in the field of EMG, US, or other more specialized disciplines as
radiology and laryngology. Besides, the guiding injection technique used is not so much
important in some instances as is the expertise of the physician in the field. In clinical practice,
the injection guidance usage also depends on the facilities and trained personal available, as
well as on the expenses incurred.
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